Since the inauguration of the second Trump administration, the federal government has initiated a comprehensive overhaul of policies, regulations, and funding mechanisms related to LGBTQ+ healthcare. This administrative shift marks a decisive departure from the "whole-of-government" equity approach of the previous four years, replacing it with a framework rooted in what the administration terms "biological reality." Through a series of executive orders, agency memoranda, and proposed rulemakings, the executive branch has moved to restrict access to gender-affirming care, eliminate diversity initiatives, and redefine sex-based protections under federal law.
The implications of these actions extend across the Department of Health and Human Services (HHS), the Department of Veterans Affairs (VA), the Department of Justice (DOJ), and the Centers for Disease Control and Prevention (CDC). While the administration argues these measures are necessary to protect children and restore fiscal accountability, medical associations and civil rights organizations have raised alarms regarding the potential for increased stigma, diminished mental health outcomes, and the erosion of patient-provider autonomy.
A New Regulatory Framework: Defining Sex and Rescinding Equity Orders
The cornerstone of the administration’s policy shift began on Day One with the rescission of several Biden-era executive actions. Specifically, Executive Order 13988, which focused on preventing discrimination based on gender identity or sexual orientation, and Executive Order 14075, which aimed to advance equality for LGBTQ+ individuals, were neutralized. These rescissions effectively dissolved the White House Gender Policy Council and signaled a move away from federal mandates requiring inclusive language and data collection.
Following these rescissions, the President issued a directive to define "sex" as an immutable biological classification. This order mandates that all federal agencies recognize only two sexes—male and female—based on reproductive biology. The order explicitly states that "sex" is not a synonym for "gender identity" and directs agencies to remove any policies or communications that promote what the administration calls "gender ideology." This has led to the removal of transgender-inclusive resources from federal websites and the expected withdrawal of sexual orientation and gender identity (SOGI) questions from federal surveys, including the Census.
Chronology of Major Executive and Agency Actions (2025–2026)
The transition has been characterized by a rapid succession of directives aimed at different sectors of the healthcare system:
- January 2025: Issuance of the "Protecting Children from Chemical and Surgical Mutilation" Executive Order. This directive sought to limit minor access to gender-affirming care (GAC) by conditioning federal research and education grants on institutions ceasing these practices for those under age 19.
- February 2025: The Department of Justice notified the Supreme Court that it would no longer support challenges against state bans on gender-affirming care, specifically reversing its position in the Tennessee litigation.
- March 2025: The VA announced a phase-out of gender-affirming care for veterans, with limited exceptions for those already receiving hormone therapy. Simultaneously, CMS issued a memorandum to hospitals questioning the evidence base for pediatric gender-affirming treatments.
- April 2025: A presidential proclamation for National Child Abuse Prevention Month categorized "gender ideology" as a form of child abuse, further escalating the rhetoric surrounding GAC.
- May 2025: HHS released a comprehensive "evidence review" that claimed the quality of evidence for gender-affirming interventions is low, a finding that contradicts the consensus of major U.S. medical organizations like the American Academy of Pediatrics (AAP) and the Endocrine Society.
- June 2025: The FBI utilized social media to urge the public to report clinics performing gender-affirming surgeries on minors, despite such procedures being legal in approximately half of U.S. states.
- January–June 2026: Proposed rules were introduced to prohibit the use of Medicaid and CHIP funds for gender-affirming care and to remove such treatments from the list of "Essential Health Benefits" (EHB) in the private insurance market.
The Targeted Restriction of Gender-Affirming Care
The administration’s most aggressive efforts have focused on gender-affirming care for minors. Proposed changes to the Hospital Conditions of Participation (CoPs) would prohibit any hospital receiving Medicare or Medicaid funding—virtually every major hospital in the U.S.—from providing puberty blockers, hormone therapy, or surgery to individuals under 18 for the purpose of gender transition.
The Centers for Medicare and Medicaid Services (CMS) has also moved to restrict coverage. A proposed rule would ban federal Medicaid and CHIP reimbursement for these services. While states could theoretically use their own funds to cover these treatments, the loss of federal matching funds would create a significant financial barrier for low-income families.
In the private sector, the administration has moved to reclassify gender-affirming care as a non-essential benefit. By removing these services from the EHB package, insurers are no longer required to count the costs of these treatments toward a patient’s deductible or out-of-pocket maximum. This change, slated for the 2026 plan year, is expected to increase the financial burden on transgender individuals who rely on the Affordable Care Act (ACA) marketplace for coverage.
Impact on Public Health Infrastructure and HIV/AIDS Programs
The policy shifts have also reached the Ryan White HIV/AIDS Program, a critical safety net for low-income individuals living with HIV. New guidance from the Health Resources and Services Administration (HRSA) reversed a Biden-era policy that allowed the program to cover certain gender-affirming services as part of "whole-person care."
The administration argues that Ryan White funds must be "marshaled exclusively toward evidence-based interventions proven to combat HIV." However, public health experts argue that for many transgender patients, gender-affirming care is the primary "entry point" into the healthcare system. By removing this component of care, the administration may inadvertently lower rates of viral suppression and care engagement among one of the populations most disproportionately affected by HIV.
Furthermore, the CDC’s updated priority statement reflects a broader shift away from "health equity." The agency now emphasizes "individual merit" over "group identity" and has deprioritized programs that document health disparities in minority populations. This change could hamper the ability of public health officials to respond to outbreaks or health crises that specifically affect LGBTQ+ communities.
Judicial Challenges and the Role of the Courts
The administration’s agenda has met significant resistance in the federal court system. Multiple lawsuits, filed by organizations such as PFLAG, Lambda Legal, the ACLU, and various healthcare providers, have resulted in a patchwork of legal stays.
In February 2025, a federal judge issued a temporary restraining order (TRO) preventing the government from withholding funding from providers who offer gender-affirming care. Another ruling in May 2025 required HHS to republish patient-safety articles that had been censored because they mentioned transgender patients.
A major legal setback for the administration occurred in March 2026, when a federal judge ruled that HHS Secretary Robert F. Kennedy Jr. overstepped his authority in declaring that gender-affirming care fails to meet professionally recognized standards of care. The court found that the Secretary cannot unilaterally redefine medical standards to bypass the expertise of professional medical associations. The ruling vacated the declaration and enjoined the administration from enforcing it against 21 plaintiff states.
Broader Implications and Societal Impact
The cumulative effect of these actions has created what many providers describe as a "chilling effect." Even in states where gender-affirming care remains legal, the threat of federal investigation, the loss of Medicaid funding, and the potential for DOJ-led fraud investigations have caused some clinics to pause or shutter their programs.
From a public health perspective, the removal of gender-affirming care is associated with heightened risks of depression, anxiety, and suicidality among transgender youth. Organizations like the Trevor Project and the American Psychological Association have warned that the administration’s rhetoric—specifically the conflation of medical care with "mutilation" or "abuse"—could exacerbate the mental health crisis facing LGBTQ+ youth.
Additionally, the decision to stop collecting SOGI data at the federal level creates a "data vacuum." Without accurate information on the health outcomes and experiences of LGBTQ+ people, it becomes nearly impossible to identify and address systemic gaps in the healthcare system.
Conclusion
The second Trump administration’s approach to LGBTQ+ health represents a fundamental re-engineering of the federal government’s relationship with sexual and gender minorities. By centralizing the definition of sex around biological binaries and aggressively targeting gender-affirming care through the levers of federal funding and regulation, the administration is seeking to dismantle a decade of inclusive policy-making. As these rules move toward finalization and legal battles continue to unfold, the ultimate landscape of LGBTQ+ healthcare in the United States remains in a state of profound flux, with significant consequences for millions of patients and their families.